Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 14.3% in March

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 221,900 shares, a growth of 14.3% from the March 15th total of 194,200 shares. Currently, 1.9% of the company’s stock are sold short. Based on an average trading volume of 224,000 shares, the days-to-cover ratio is presently 1.0 days.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Roth Capital reiterated a “buy” rating on shares of Chemomab Therapeutics in a report on Tuesday, December 19th. Roth Mkm reiterated a “buy” rating and issued a $7.00 price objective on shares of Chemomab Therapeutics in a research note on Tuesday, December 19th.

Institutional Trading of Chemomab Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CMMB. Boothbay Fund Management LLC increased its stake in shares of Chemomab Therapeutics by 38.1% during the 4th quarter. Boothbay Fund Management LLC now owns 51,608 shares of the company’s stock worth $165,000 after purchasing an additional 14,237 shares during the last quarter. Two Sigma Investments LP bought a new stake in Chemomab Therapeutics in the first quarter worth $48,000. Renaissance Technologies LLC acquired a new position in Chemomab Therapeutics during the first quarter worth $134,000. Citadel Advisors LLC bought a new position in Chemomab Therapeutics during the third quarter valued at about $53,000. Finally, Envestnet Asset Management Inc. bought a new position in Chemomab Therapeutics during the first quarter valued at about $52,000. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Chemomab Therapeutics Trading Up 1.3 %

NASDAQ CMMB traded up $0.01 on Friday, reaching $0.77. The stock had a trading volume of 11,602 shares, compared to its average volume of 52,886. Chemomab Therapeutics has a 1 year low of $0.42 and a 1 year high of $1.89. The business has a 50 day moving average price of $0.72 and a 200 day moving average price of $0.66. The company has a market capitalization of $8.51 million, a price-to-earnings ratio of -0.36 and a beta of 0.36.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.14. During the same period last year, the business earned ($0.72) EPS. On average, analysts anticipate that Chemomab Therapeutics will post -1.2 earnings per share for the current fiscal year.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).